Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Part of paid clinical trials in Los Angeles, California.

Sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Study ID
NCT07517198
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Gastric Cancer
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Hepatic Cancer
  • High Grade Neuroendocrine Cancer
  • Non-small Cell Lung Cancer (NSCLC)
  • Ovarian Cancer
  • Prostate Cancer
  • Renal Carcinoma (Clear and Non-clear Cell)
  • Small Cell Carcinomas of Non-lung Origin
  • Small Cell Lung Cancer (SCLC)
  • Solid Tumor
  • Triple-negative Breast Cancer (TNBC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • EXS74539 — DRUG
    Oral administration

Study Details

The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

Key Dates

Start date
Apr 13, 2026
Status verified
Jun 2026
Primary completion
Mar 31, 2029
Completion
Mar 31, 2029

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: EXS74539
    EXS74539

Primary Outcome Measure

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to 3 years ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Start LacnLos AngelesCalifornia90025-
START DallasFort WorthTexas76104-
START Mountain RegionWest Valley CityUtah84119-

Find similar trials in Los Angeles, CA

By condition
Gastric cancerOvarian cancerProstate cancer
By specialty
OncologyGI oncologyGynecologic oncologyWomen's healthProstate oncologyMen's healthUrology
By research site
Start Lacn· Los Angeles, CASTART Dallas· Fort Worth, TXSTART Mountain Region· West Valley City, UT

Related Studies